Persistence of Lamivudine-Sensitive HIV-1 Quasispecies in the Presence of Lamivudine In Vitro and In Vivo
暂无分享,去创建一个
K. Metzner | H. Günthard | H. Walter | M. Fischer | M. Opravil | P. Rauch | Stefanie A Knoepfel | K. Allers | Kristina Allers
[1] C. Boucher,et al. A novel real-time PCR assay to determine relative replication capacity for HIV-1 protease variants and/or reverse transcriptase variants. , 2006, Journal of virological methods.
[2] L. Alexander,et al. The contribution of HIV fitness to the evolution pattern of reverse transcriptase inhibitor resistance , 2006, Journal of medical virology.
[3] M. Vignuzzi,et al. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population , 2006, Nature.
[4] Hauke Walter,et al. Detection of minor populations of drug-resistant HIV-1 in acute seroconverters , 2005, AIDS.
[5] E. Arts,et al. Replicative fitness of historical and recent HIV-1 isolates suggests HIV-1 attenuation over time , 2005, AIDS.
[6] Jonathan AC Sterne,et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study , 2005, The Lancet.
[7] Matthew C Strain,et al. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. , 2005, The Journal of infectious diseases.
[8] Tara L. Kieffer,et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. , 2005, JAMA.
[9] H. Günthard,et al. Cellular viral rebound after cessation of potent antiretroviral therapy predicted by levels of multiply spliced HIV-1 RNA encoding nef. , 2004, The Journal of infectious diseases.
[10] A. Molla,et al. Complementation in Cells Cotransfected with a Mixture of Wild-Type and Mutant Human Immunodeficiency Virus (HIV) Influences the Replication Capacities and Phenotypes of Mutant Variants in a Single-Cycle HIV Resistance Assay , 2004, Journal of Clinical Microbiology.
[11] R. Grant,et al. The clinical implications of reduced viral fitness , 2004, Current infectious disease reports.
[12] B. Berkhout,et al. Human Immunodeficiency Virus Type 1 Subtypes Have a Distinct Long Terminal Repeat That Determines the Replication Rate in a Host-Cell-Specific Manner , 2004, Journal of Virology.
[13] H. Günthard,et al. Attenuated and nonproductive viral transcription in the lymphatic tissue of HIV-1-infected patients receiving potent antiretroviral therapy. , 2004, The Journal of infectious diseases.
[14] S. Deeks,et al. Treatment of antiretroviral-drug-resistant HIV-1 infection , 2003, The Lancet.
[15] Alan S. Perelson,et al. Viral Blip Dynamics during Highly Active Antiretroviral Therapy , 2003, Journal of Virology.
[16] K. Metzner,et al. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. , 2003, The Journal of infectious diseases.
[17] R. Siliciano,et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells , 2003, Nature Medicine.
[18] D. Richman,et al. Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: Intrinsic stability predicts lifelong persistence , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[19] R. Lempicki,et al. Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[20] M. Hirsch,et al. Prevalence and predictive value of intermittent viremia with combination hiv therapy. , 2001, JAMA.
[21] Jiasen Lu,et al. A Novel Recombinant Marker Virus Assay for Comparing the Relative Fitness of HIV‐1 Reverse Transcriptase Variants , 2001, Journal of acquired immune deficiency syndromes.
[22] A. Trkola,et al. Residual Cell-Associated Unspliced HIV-1 Rna in Peripheral Blood of Patients on Potent Antiretroviral Therapy Represents Intracellular Transcripts , 2001, Antiviral therapy.
[23] M. Malim,et al. Human Immunodeficiency Virus Type 1 Spinoculation Enhances Infection through Virus Binding , 2000, Journal of Virology.
[24] E. Arts,et al. A Dual Infection/Competition Assay Shows a Correlation between Ex Vivo Human Immunodeficiency Virus Type 1 Fitness and Disease Progression , 2000, Journal of Virology.
[25] E. Rosenberg,et al. Antiretroviral resistance during successful therapy of HIV type 1 infection. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[26] S. Frost,et al. Evolution of Lamivudine Resistance in Human Immunodeficiency Virus Type 1-Infected Individuals: the Relative Roles of Drift and Selection , 2000, Journal of Virology.
[27] A. Perelson,et al. Effects of in Vivo Cd8+ T Cell Depletion on Virus Replication in Rhesus Macaques Immunized with a Live, Attenuated Simian Immunodeficiency Virus Vaccine , 2000, The Journal of experimental medicine.
[28] R. Weber,et al. Effects of Early Antiretroviral Treatment on HIV‐1 RNA in Blood and Lymphoid Tissue: A Randomized Trial of Double Versus Triple Therapy , 2000, Journal of acquired immune deficiency syndromes.
[29] Alan S. Perelson,et al. Evolution of Envelope Sequences of Human Immunodeficiency Virus Type 1 in Cellular Reservoirs in the Setting of Potent Antiviral Therapy , 1999, Journal of Virology.
[30] A. Perelson,et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. , 1999, The New England journal of medicine.
[31] M. Fischer,et al. Highly Sensitive Methods for Quantitation of Human Immunodeficiency Virus Type 1 RNA from Plasma, Cells, and Tissues , 1999, Journal of Clinical Microbiology.
[32] J. Lisziewicz,et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy , 1999, Nature Medicine.
[33] A. Telenti,et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study , 1999, The Lancet.
[34] P. Kissinger,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.
[35] T. Chun,et al. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[36] G. Satten,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.
[37] D. Richman,et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.
[38] R Brookmeyer,et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.
[39] S. Yerly,et al. Detection of low HIV-1 RNA levels in plasma. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[40] A S Perelson,et al. Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase , 1996, Journal of virology.
[41] W. Keulen,et al. Reduced replication of 3TC‐resistant HIV‐1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. , 1996, The EMBO journal.
[42] B. Berkhout,et al. Nucleotide substitution patterns can predict the requirements for drug-resistance of HIV-1 proteins. , 1996, Antiviral research.
[43] J. Sninsky,et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). , 1995, The Journal of infectious diseases.
[44] J. Coffin,et al. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.
[45] A. Perelson,et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.
[46] Martin A. Nowak,et al. Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.
[47] M. Wainberg,et al. High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase , 1993, Antimicrobial Agents and Chemotherapy.
[48] R F Schinazi,et al. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides , 1993, Antimicrobial Agents and Chemotherapy.
[49] K. Metzner,et al. Inhibition of drug-resistant HIV-1 by RNA interference. , 2006, Antiviral research.
[50] R. Siliciano,et al. The challenge of viral reservoirs in HIV-1 infection. , 2002, Annual review of medicine.
[51] P. Vernazza,et al. Effects of early antiretroviral treatment on HIV-1 RNA in blood and lymphoid tissue: a randomized trial of double versus triple therapy. Swiss HIV Cohort Study. , 2000 .